

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,  
INC. and AKORN INC.,<sup>1</sup>  
Petitioners,

v.

ALLERGAN, INC.,  
Patent Owner.

---

Case IPR2016-01127 (US 8,685,930 B2)  
Case IPR2016-01128 (US 8,629,111 B2)  
Case IPR2016-01129 (US 8,642,556 B2)  
Case IPR2016-01130 (US 8,633,162 B2)  
Case IPR2016-01131 (US 8,648,048 B2)  
Case IPR2016-01132 (US 9,248,191 B2)

---

**PETITIONERS' REQUEST FOR ORAL ARGUMENT PURSUANT  
TO 37 C.F.R. § 42.70**

---

<sup>1</sup> Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599, IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601, have respectively been joined with the captioned proceedings. The word-for-word identical paper is filed in each proceeding identified in the caption pursuant to the Board's Scheduling Order (Paper 10).

Pursuant to 37 C.F.R. § 42.70(a), Petitioners Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., and Akorn Inc. hereby provide this Request for Oral Argument regarding the unpatentability of the involved claims of U.S. Patent Nos. 8,685,930; 8,629,111; 8642,556; 8633,162; 8648,048; and 9,248,191 on the instituted grounds and on any pending motions.

Petitioners requests no more than 90 minutes per side of oral argument. The Oral Argument will be held August 17, 2017, pursuant to the Scheduling Order (Paper 10).

Respectfully submitted,

Date: July 20, 2017

/ Steven W. Parmelee /

Steven W. Parmelee

Reg. No. 31,990

## CERTIFICATE OF SERVICE

This is to certify that I caused to be served a true and correct copy of the foregoing Petitioners' Request for Oral Argument Pursuant to 37 C.F.R. § 42.70 on this 20<sup>th</sup> day of July, 2017, on the Patent Owner at the correspondence address of the Patent Owner as follows:

Dorothy P. Whelan  
Michael Kane  
Susan Morrison Colletti  
Robert M. Oakes  
Jonathan Singer  
Fish & Richardson P.C.  
3200 RBC Plaza  
60 South Sixth Street  
Minneapolis, MN 55402  
Email: [IPR13351-0008IP1@fr.com](mailto:IPR13351-0008IP1@fr.com)  
Email: [IPR13351-0008IP2@fr.com](mailto:IPR13351-0008IP2@fr.com)  
Email: [IPR13351-0008IP3@fr.com](mailto:IPR13351-0008IP3@fr.com)  
Email: [IPR13351-0008IP4@fr.com](mailto:IPR13351-0008IP4@fr.com)  
Email: [IPR13351-0008IP5@fr.com](mailto:IPR13351-0008IP5@fr.com)  
Email: [IPR13351-0008IP6@fr.com](mailto:IPR13351-0008IP6@fr.com)  
Email: [PTABInbound@fr.com](mailto:PTABInbound@fr.com)

And on the remaining petitioners as follows:

Gary Speier  
Mark Schuman  
CARLSON, CASPERS, VANDENBURGH,  
LINDQUIST & SCHUMAN, P.A.  
225 South Sixth Street, Suite 4200  
Minneapolis, MN 55402  
Email: [gspeier@carlsoncaspers.com](mailto:gspeier@carlsoncaspers.com)  
Email: [mschuman@carlsoncaspers.com](mailto:mschuman@carlsoncaspers.com)  
*Attorneys for Teva Pharmaceuticals USA, Inc.*

Michael Dzwonczyk  
Azadeh Kokabi  
Travis Ribar  
SUGHRUE MION, PLLC  
2100 Pennsylvania Ave., NW  
Washington, DC 20037  
Email: [mdzwonczyk@sughrue.com](mailto:mdzwonczyk@sughrue.com)  
Email: [akokabi@sughrue.com](mailto:akokabi@sughrue.com)  
Email: [tribar@sughrue.com](mailto:tribar@sughrue.com)  
*Attorneys for Akorn Inc.*

Respectfully submitted,

Dated: July 20, 2017

/ Steven W. Parmelee /  
Steven W. Parmelee, Lead Counsel  
Reg. No. 31,990